Qube Research & Technologies (QRT)’s AbCellera Biologics ABCL Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-122,592	Closed	-$419K	–	3482
2025 Q4	$419K	Buy	+122,592	New	+$547K	﹤0.01%	2854
2023 Q4	–	Sell	-26,967	Closed	-$124K	–	4297
2023 Q3	$124K	Buy	+26,967	New	+$164K	﹤0.01%	2583
2023 Q2	–	Sell	-95,621	Closed	-$721K	–	2335
2023 Q1	$721K	Sell	95,621 -162,896	-63%	-$1.48M	﹤0.01%	1421
2022 Q4	$2.62M	Buy	258,517 +206,750	+399%	+$2.39M	0.01%	857
2022 Q3	$512K	Buy	+51,767	New	+$568K	﹤0.01%	1456
2022 Q2	–	Sell	-149,417	Closed	-$1.46M	–	2429
2022 Q1	$1.46M	Buy	149,417 +129,744	+660%	+$1.23M	0.01%	969
2021 Q4	$281K	Buy	+19,673	New	+$299K	﹤0.01%	1831

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ABCL Position: Q1 2026 in Review

Qube Research & Technologies (QRT) sold out of AbCellera Biologics (ABCL) in Q1 2026, closing a stake of 122,592 shares — an estimated $419K sold.

Qube Research & Technologies (QRT) first reported a position in ABCL in Q4 2021 and held it in 7 quarters. The position peaked at $2.62M in Q4 2022. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

Qube Research & Technologies (QRT) reported no remaining AbCellera Biologics position as of Q1 2026 after selling out during the quarter.
Qube Research & Technologies (QRT) sold 122,592 AbCellera Biologics shares in Q1 2026, an estimated $419K.
Qube Research & Technologies (QRT) first reported a position in AbCellera Biologics in Q4 2021 and held it in 7 quarters.
Qube Research & Technologies (QRT)'s AbCellera Biologics position peaked at $2.62M in Q4 2022.
138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.